Dezhan Healthcare (000813) Stock Overview
Engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
000813 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Dezhan Healthcare Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.39 |
| 52 Week High | CN¥5.26 |
| 52 Week Low | CN¥2.70 |
| Beta | 0.33 |
| 1 Month Change | 6.55% |
| 3 Month Change | 30.65% |
| 1 Year Change | 43.93% |
| 3 Year Change | 42.53% |
| 5 Year Change | -28.62% |
| Change since IPO | -55.39% |
Recent News & Updates
Recent updates
There's Reason For Concern Over Dezhan Healthcare Company Limited's (SZSE:000813) Massive 34% Price Jump
Dec 10
Dezhan Healthcare's (SZSE:000813) Shareholders May Want To Dig Deeper Than Statutory Profit
Nov 06Dezhan Healthcare Company Limited's (SZSE:000813) Share Price Could Signal Some Risk
Oct 25We Like The Quality Of Dezhan Healthcare's (SZSE:000813) Earnings
Apr 18Shareholder Returns
| 000813 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 4.8% | -1.2% | 0.6% |
| 1Y | 43.9% | 17.6% | 24.1% |
Return vs Industry: 000813 exceeded the CN Pharmaceuticals industry which returned 17.6% over the past year.
Return vs Market: 000813 exceeded the CN Market which returned 24.1% over the past year.
Price Volatility
| 000813 volatility | |
|---|---|
| 000813 Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 000813's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 000813's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 1,054 | Wei Liu | www.dezhanhealthcare.com |
Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People’s Republic of China. The company offers atorvastatin calcium tablets, amlodipine atorvastatin calcium tablets, trimetazidine hydrochloride capsules, amiodarone hydrochloride tablets, as well as other drugs, including famciclovir tablets, azathioprine tablets, and hydroxyurea tablets and colchicine tablet. It is also involved in the provision of biological peptides, industrial hemp, and medical service business; and food and beverages, and cosmetics under the Hanhui, Xiao Lan, Ruyin Fangxing, and Ma Yuansu brands.
Dezhan Healthcare Company Limited Fundamentals Summary
| 000813 fundamental statistics | |
|---|---|
| Market cap | CN¥9.21b |
| Earnings (TTM) | -CN¥73.49m |
| Revenue (TTM) | CN¥384.52m |
Is 000813 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000813 income statement (TTM) | |
|---|---|
| Revenue | CN¥384.52m |
| Cost of Revenue | CN¥148.13m |
| Gross Profit | CN¥236.40m |
| Other Expenses | CN¥309.89m |
| Earnings | -CN¥73.49m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 25, 2025
| Earnings per share (EPS) | -0.035 |
| Gross Margin | 61.48% |
| Net Profit Margin | -19.11% |
| Debt/Equity Ratio | 2.3% |
How did 000813 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/02 19:29 |
| End of Day Share Price | 2025/09/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dezhan Healthcare Company Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiangyang Du | Industrial Securities Co. Ltd. |